- Conditions
- Weight Loss, Weight Prejudice
- Interventions
- Internalized Weight Bias Intervention
- Behavioral
- Lead sponsor
- East Carolina University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Metformin, Placebo, Lifestyle Intervention
- Drug · Behavioral
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 12 Years to 39 Years · Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 1,093 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 64
- States / cities
- Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more
- Conditions
- Solid Tumor, Adult
- Interventions
- IO-202, IO-202 + pembrolizumab combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types
- Biological
- Lead sponsor
- Immune-Onc Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Gainesville, Florida • Chicago, Illinois + 7 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Isatuximab SAR650984, Bortezomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 5
- States / cities
- Fort Myers, Florida • St. Petersburg, Florida • Kansas City, Missouri + 2 more
- Conditions
- Prostate Cancer
- Interventions
- filgrastim, carmustine, cisplatin, melphalan, vinorelbine tartrate, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Liver Cirrhosis
- Interventions
- Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more
- Conditions
- Migraine
- Interventions
- Simvastatin, Vitamin D, Placebo
- Drug · Dietary Supplement · Other
- Lead sponsor
- Rami Burstein
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fragile X Syndrome
- Interventions
- Metformin, Placebo oral tablet
- Drug
- Lead sponsor
- Rowan University
- Other
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Stratford, New Jersey
- Conditions
- HIV Infections
- Interventions
- Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1995
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Tumor, Solid
- Interventions
- Durvalumab and Tremelimumab
- Drug
- Lead sponsor
- John L. Villano, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Metastasis
- Interventions
- THOR-707, Checkpoint inhibitor, anti-EGFR antibody
- Drug
- Lead sponsor
- Synthorx, Inc, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Entinostat, Enzalutamide
- Drug
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Prostate Cancer
- Interventions
- Flutamide, Leuprolide Acetate
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Developmental Language Disorder, Language Impairment
- Interventions
- Sentence recast
- Behavioral
- Lead sponsor
- University of Houston
- Other
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Interventions
- 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab
- Drug
- Lead sponsor
- CytoDyn, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Irvine, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
- Conditions
- Acne Vulgaris
- Interventions
- Adapalene/benzoyl peroxide gel, 0.1%/2.5%, Cetaphil Acne Regimen
- Drug · Other
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Pflugerville, Texas
- Conditions
- Secondary Osteoporosis, Sarcopenia
- Interventions
- Exoskeleton-Assisted Walking (EAW) + active Transcutaneous Spinal Cord Stimulation (tSCS), Exoskeleton-assisted walking (EAW) + sham Transcutaneous Spinal Cord Stimulation (tSCS)
- Device
- Lead sponsor
- Bronx VA Medical Center
- Federal
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- West Orange, New Jersey
- Conditions
- Plasma Cell Myeloma
- Interventions
- Isatuximab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Plantation, Florida • Boston, Massachusetts
- Conditions
- Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma, Round Cell Liposarcoma, Myxoid Pleomorphic Liposarcoma, Pleomorphic Liposarcoma, Unresectable Liposarcoma, Unresectable Dedifferentiated Liposarcoma
- Interventions
- Mirdametinib, Palbociclib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- CT-322, Temozolomide, Radiation Therapy
- Drug · Procedure
- Lead sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Chicago, Illinois • Lexington, Kentucky + 3 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
- Interventions
- dimethyl fumarate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Danbury, Connecticut + 13 more
- Conditions
- Brain Neoplasms
- Interventions
- Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo
- Drug · Radiation · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 716 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
- Conditions
- Giant Cell Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Glioblastoma, Small Cell Glioblastoma
- Interventions
- autologous dendritic cells pulsed with tumor lysate antigen Vaccine, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California